

APPENDIX 4D – HALF YEAR REPORT GIVEN TO ASX UNDER LISTING RULE 4.2A.3 FOR THE 6 MONTH PERIOD ENDED 30 JUNE 2017

Item	Contents
1	Details of the reporting period
2	Results for announcement to the market
3	Net tangible assets per security
4	Dividends and distributions
5	Other information

1. DETAILS OF THE REPORTING PERIOD

Reporting period: 6 month period ended 30 June 2017

Previous corresponding period: 6 month period ended 30 June 2016

2. RESULTS FOR ANNOUNCEMENT TO THE MARKET

	30 June 2017 €	30 June 2016 €	Up/(down) €	% change
Recurring Revenue	1,278,253	630,165	648,088	103%
Non Recurring Revenue	950,722	4,361,803	3,411,081	(78%)
Total Revenue	2,228,975	4,991,968	(2,762,993)	(55%)
(Loss) after tax attributable to members	(14,251,946)	(5,924,819)	(8,327,127)	(140%)
Net (Loss) for the period attributable to members	(14,251,946)	(5,924,819)	(8,327,127)	(140%)

The Company has not declared, and does not propose to pay, any dividends for the period ended 30 June 2017.

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

As at 30 June 2017, the Oneview system was live in 3,000 beds (30 June 2016: 1,671) with a further 3,812 beds contracted but not yet installed (30 June 2016: 3,291). There were a further 5,633 beds in contract negotiation (30 June 2016: 2,836) and 11,466 in tender process (30 June 2016: 7,439). During the period, Oneview announced a number of contract successes with new hospitals including BJC Healthcare and Lancaster General Hospital. Oneview has signed an enterprise agreement with BJC Healthcare for 2,000 devices to be installed over a 3 year period, starting with an initial 381 beds to be installed in 2017. The Lancaster General Hospital agreement includes the installation of the Oneview Solution across 631 beds. Oneview continues to grow its pipeline of new business opportunities across the four territories in which the Group currently operates. The first revenues have been recognized for the CONNECT product in the period and the opportunities for this product are expected to expand in the near future.

Following the company's IPO, the business has continued to invest in attracting world-class employees across each of its primary office locations and has increased the headcount to 178 personnel as at 30 June

2017 from 104 at 30 June 2016. The growth in headcount has primarily been in the areas of technology and sales teams to keep supporting the Groups continued growth.

Oneview continues to receive high engagement with a number of pre-eminent healthcare providers and progress its sales pipeline. However, progress in the first half of 2017 has been slower than expected due to uncertainty in the US healthcare market arising in part from the healthcare policies of the new US Administration and resulting longer decision making lead times. Revenue for the period amounted to €2,228,975 (30 June 2016: €4,991,968). Recurring revenue for the period amounted to €1,278,254 (30 June 2016: €630,165) an increase of 103% and continues to grow as the company deploys across its increasing customer base. Non-recurring revenue for the period was €950,722 (30 June 2016: €4,361,803) a decline of 78%. During the period, the company continued implementation across the following hospitals or hospital systems:

- Epworth HealthCare Group in Melbourne, Australia
- The Sydney Children's Hospital Network at Westmead in Sydney,
- Barnes Jewish Christian (BJC) Healthcare
- University of Iowa Children's Hospital
- NYU Langone Medical Centre

For further information, please see the Directors Report in the Interim Financial Results.

3. NET TANGIBLE ASSETS PER SECURITY

	6 month period ended 30 June 2017	6 month period ended 30 June 2016	% change
Net tangible assets per security	€0.41	€0.81	(51%)

Net tangible assets are defined as the net assets of Oneview Healthcare Plc less intangible assets. A small proportion of the Company's assets are intangible in nature. These assets are excluded from the calculation of net tangible assets per security shown above.

4. DIVIDENDS AND DISTRIBUTIONS

The Company did not pay any distributions during the 6 month period ended 30 June 2017. The Company has not declared any distributions for the 6 month period ended 30 June 2016.

5. OTHER INFORMATION

Details of entities over which control has been gained or lost during the 6 months to 30 June 2017: N/A

Details of any dividend or distribution reinvestment plans in operation: N/A

Details of associates and joint venture entities: N/A

The interim financial statements for the half year ended 30 June 2017 forms part of and should be read in conjunction with this half year report (Appendix 4D). The unaudited condensed consolidated financial report has been prepared in accordance with IAS 34 Interim Financial Reporting as adopted by the European Union. Any other information required pursuant to ASX Listing Rule 4.2A not contained in this Appendix 4D is found in the attached Interim Financial Report.